Atossa Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Net cash plus modest risk-adjusted pipeline value: $26.09M net cash ($2.61/share); pipeline value of approximately $20M reflecting a risk-adjusted NPV of the lead asset (Z)-endoxifen, assuming roughly $250-300M un-risked commercial NPV, an 8-10% phase-2-to-approval probability, discounted about 8 years at 12%; 9.98M shares outstanding.

Reasoning: Atossa Therapeutics is pre-revenue and cash-burning with under a year of runway, so a DCF is not meaningful; net cash is the dominant verifiable component with only a small risk-adjusted allowance for its Phase 2 oncology asset given high clinical attrition rates.